FAS has cancelled previously agreed prices for Clopidogrel-Teva


The Federal Antimonopoly Service (FAS) of Russia has refused to agree on the maximum selling price for Teva Russia’s Clopidogrel-Teva. As the FAS press service reported, the agency also canceled previously agreed prices for this medicine.

“The economic analysis performed by the service showed that the stated maximum selling price and previously agreed prices for other packages of this drug are higher than the selling prices in Hungary and the Netherlands. The antimonopoly authority refused to approve the stated price. In addition, since the company did not reduce the previously agreed prices to the level of the said countries, in accordance with the rules of price registration, the service canceled its earlier decisions on price approval,” the statement reads.

According to the antimonopoly service, the Russian drug market has the necessary amount of this drug supplied by other manufacturers.

Clopidogrel-Teva is prescribed to patients with myocardial infarction, ischemic stroke and diagnosed occlusive peripheral arterial disease.

The Federal Antimonopoly Service had previously agreed on the price of Cabatax, an antitumor drug.